All stock lists
Enlivex Ltd. (NASDAQ:ENLV)
IL · Delayed Price · Currency is USD
Also listed: ENLV.TAHealthcare · Biotechnology
1.78-0.76 (-29.92%)
Market cap
$30.0M
Insider Score
Health Score
Analyst consensus
Listed since
Jul 31, 2014
Website
Insider Score
––Not scored
ENLV Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Fair
From ENLV’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars
Profitability—
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- $4.11B
- Net margin
- —
Leverage20 / 20
Little or no net debt.
- Total debt
- $17.2M
- Cash
- $5.5M
- Debt / equity
- 0.00
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $3.75B
- Current liabilities
- $31.4M
- Current ratio
- 119.39
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$15.8M
- Free cash flow
- -$16.2M
Dilution & runway0 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 1.0M
- Share growth (1y)
- 940.1%
- Cash runway
- 4 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ENLV Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 57.00 K | 0.00 | 76.00 K | 81.00 K | 85.00 K | 90.00 K |
| Gross Profit | -57.00 K | 0.00 | -76.00 K | -81.00 K | -85.00 K | -90.00 K |
| SG&A Expense | 1.31 M | 4.60 M | 2.72 M | 1.07 M | 937.00 K | 954.00 K |
| R&D Expense | 2.92 M | 3.31 M | 3.03 M | 1.48 M | 2.14 M | 2.55 M |
| Operating Expenses | 4.17 M | 7.91 M | 5.79 M | 2.48 M | 2.99 M | 3.53 M |
| Operating Income | -4.23 M | -7.91 M | -5.86 M | -2.56 M | -3.08 M | -3.53 M |
| Pretax Income | 2.46 B | 1.27 B | 1.63 B | -2.21 M | -1.87 M | -3.45 M |
| Tax Provision | 566.70 M | 293.65 M | 382.65 M | 0.00 | 0.00 | 0.00 |
| Net Income | 1.89 B | 974.52 M | 1.24 B | -2.21 M | -1.87 M | -3.45 M |
| EPS (Basic) | 1829.76 | 868.00 | 6564.00 | -22.08 | -18.72 | -38.40 |
| EPS (Diluted) | 1564.80 | 868.00 | 6189.60 | -22.08 | -18.72 | -38.40 |
| Shares Outstanding | 1.03 M | 1.12 M | 189.35 K | 100.19 K | 99.40 K | 91.23 K |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.